[{"arm_notes": "", "treatment_id": null, "treatment_name": "Adults (18-59 years old):Subjects were randomly assigned to the low-dose; high-dose; and placebo groups in a ratio of 2:2:1 (the low-dose and high-dose groups were the medium and high-dose groups in the Phase I clinical trial). All subjects received one dose of the trial vaccine or placebo (an excipient without antigen).;Elderly (>=60 years old):Subjects were randomly assigned to the low-dose; high-dose; and placebo groups in a ratio of 2:2:1 (the low-dose and high-dose groups were the medium and high-dose groups in the Phase I clinical trial). All subjects received one dose of the trial vaccine or placebo (an excipient without antigen).;", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Adults (18-59 years old):Subjects were randomly assigned to the low-dose; high-dose", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "and placebo groups in a ratio of 2:2:1 (the low-dose and high-dose groups were the medium and high-dose groups in the Phase I clinical trial). All subjects received one dose of the trial vaccine or placebo (an excipient without antigen).", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Elderly (>=60 years old):Subjects were randomly assigned to the low-dose; high-dose", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "and placebo groups in a ratio of 2:2:1 (the low-dose and high-dose groups were the medium and high-dose groups in the Phase I clinical trial). All subjects received one dose of the trial vaccine or placebo (an excipient without antigen).;", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "Low dose;1;18-59 years old", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "High dose;1;18-59 years old", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Low dose;1;18-59 years old", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "High dose;1;18-59 years old", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]